

Announcement Summary

Entity name

MGC PHARMACEUTICALS LTD

Announcement Type

New announcement

Date of this announcement

Tuesday November 01, 2022

The +securities to be quoted are: ☑ Other

Total number of +securities to be quoted

	SX +security ode	Security description	Number of +securities to be quoted	Issue date
м	IXC	ORDINARY FULLY PAID	15,000,000	01/11/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

MGC PHARMACEUTICALS LTD

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type ABN Registration number 30116800269

1.3 ASX issuer code MXC

1.4 The announcement is

C New announcement

1.5 Date of this announcement

1/11/2022



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

C Other

2.2 The +securities to be quoted are:

C Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS? $\textcircled{\sc No}$ No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The securities have been issued in lieu of payments to employee/consultants of Company in order for the Company to preserve working capital. Approval to issue the securities was received on the same day on which the securities were issued, as such an Appendix 3B was not deemed necessary as this Appendix 2A would be issued on the same day.



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an

Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description MXC : ORDINARY FULLY PAID

Issue date

1/11/2022

Issue details

Number of +securities to be quoted

15,000,000

Are the +securities being issued for a cash consideration?

🕑 No

Please describe the consideration being provided for the +securities

The securities are being issued to employees for services rendered, in lieu of cash payment.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.014000

Any other information the entity wishes to provide about the +securities to be quoted

The purpose(s) for which the entity is issuing the securities

To pay for services rendered

Please provide additional details

The securities are being issued to employees for services rendered, in lieu of cash payment.



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
MXC : ORDINARY FULLY PAID	2,865,647,321

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MXCAF : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	60,300,000
MXCAG : PERFORMANCE RIGHTS	22,275,000
MXCAAA : CONVERTIBLE NOTES	4,850,000
MXCAAC : CLASS B PERFORMANCE RIGHTS	39,900,000
MXCAAD : CLASS C PERFORMANCE RIGHTS	6,000,000
MXCAH : OPTION EXPIRING 31-MAR-2023 EX \$0.026	7,692,308
MXCAI : OPTION EXPIRING 31-MAR-2023 EX GBP0.01475	26,440,678
MXCAAE : CLASS D PERFORMANCE RIGHTS	250,000
MXCAAF : CLASS E PERFORMANCE RIGHTS	250,000



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? S No

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

15,000,000

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? ⓒ No